1. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.
- Author
-
Tomoko Okada, Kazuhiro Murata, Ryoma Hirose, Chie Matsuda, Tsunehiko Komatsu, Masahiko Ikekita, Miyako Nakawatari, Fumiaki Nakayama, Masaru Wakatsuki, Tatsuya Ohno, Shingo Kato, Takashi Imai, and Toru Imamura
- Subjects
FIBROBLAST growth factors ,PLATINUM ,HELA cells ,BIOPSY ,CERVICAL cancer treatment ,CISPLATIN ,CANCER chemotherapy ,THERAPEUTICS - Abstract
Cancer cells often develop drug resistance. In cisplatin-resistant HeLa cisR cells, fibroblast growth factor 13 (FGF13/FHF2) gene and protein expression was strongly upregulated, and intracellular platinum concentrations were kept low. When the FGF13 expression was suppressed, both the cells' resistance to platinum drugs and their ability to keep intracellular platinum low were abolished. Overexpression of FGF13 in parent cells led to greater resistance to cisplatin and reductions in the intracellular platinum concentration. These cisplatin-resistant cells also showed increased resistance to copper. In preoperative cervical cancer biopsy samples from poor prognoses patients after cisplatin chemoradiotherapy, FGF13-positive cells were detected more abundantly than in the biopsy samples from patients with good prognoses. These results suggest that FGF13 plays a pivotal role in mediating resistance to platinum drugs, possibly via a mechanism shared by platinum and copper. Our results point to FGF13 as a novel target and useful prognostic guide for cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF